News

Latest Publications

Aurealis Therapeutics Developing a Drug Therapy with Multiple Active Substances in One Product Has Initiated Repeated Dosing Groups in the Diabetic Foot Ulcer Patient Trial

Basel Switzerland, Kuopio Finland – November 17th, 2020. Aurealis Therapeutics, a private clinical-stage biopharmaceutical company, is making a difference in chronic, non-healing wounds by developing a therapy with multiple active substances in one product that are hitting all key pathomechanisms. Chronic wound care needs curative drugs with true active pharmaceutical substances, not just incrementally improved … Aurealis Therapeutics Developing a...

Read

Aurealis Therapeutics to Strengthen Its Board of Directors by Appointing Dr. Laurent Décory, an Experienced Advanced Wound Care Industry Executive

Basel Switzerland, Kuopio Finland – June 17th, 2020. Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the four-in-one biologic drug for chronic non-healing wounds and regenerative diseases, announced today that Mr. Laurent Décory has joined the Board of Directors of the company as of June 10th, 2020. Existing Board Directors Iain Buchanan, Silvio Inderbitzin … Aurealis Therapeutics to Strengthen...

Read

AUREALIS THERAPEUTICS PIONEERING MULTIPLE DRUG PRODUCING BACTERIA AUP-16 DOSED TO THE FIRST DIABETIC FOOT ULCER PATIENT IN THE PHASE 1-2A TRIAL

Basel Switzerland, Kuopio Finland – February 11th, 2020. Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today that the first diabetic foot ulcer (DFU) patient has been dosed with AUP-16. The trial is performed in non-healing DFU patients and is designed … AUREALIS THERAPEUTICS PIONEERING MULTIPLE...

Read

Aurealis Therapeutics Receives Clinical Trial Application Approval for AUP-16 Diabetic Foot Ulcer Patient Trial

Basel Switzerland, Kuopio Finland – September 27th, 2019. Aurealis Therapeutics, a private biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today clinical trial application (CTA) approval of the AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. The company plans … Aurealis Therapeutics Receives Clinical...

Read

Aurealis Therapeutics Receives Clinical Trial Application Approval for AUP-16 Diabetic Foot Ulcer Patient Trial

Basel Switzerland, Kuopio Finland – September 27th, 2019. Aurealis Therapeutics, a private biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today clinical trial application (CTA) approval of the AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. The company plans … Aurealis Therapeutics Receives Clinical...

Read

Be the first
to know
our updates

Sign Up

Contact us